Pneumonia Therapeutics Market Size 2022- Industry Growth Demand and Forecast 2032

Pneumonia Therapeutics Market Size- By Therapeutics, By Distribution Channel, By Age Group, By Infection Type - Regional Outlook, Competitive Strategies and Segment Forecasts to 2032

Published: Nov 2022 Base Year: 2021 Report ID: HLCA2217
Available Format: Historical Data: 2019 - 2020 Number of Pages: 1 - 256
Category : Health Care
Global Pneumonia Therapeutics Market Overview:

According to SPER Market Research, the Global Pneumonia Therapeutics Market is estimated to reach USD 42.62 billion by 2032 with a CAGR of 8.3%. 

An infection that affects the lower respiratory system is pneumonia. Additionally, pneumonia exhibits symptoms including shortness of breath, fever, chest discomfort, nausea, and vomiting. Alveoli, the lungs' air sacs, are filled with fluid or pus in pneumonia, which results in inflammation. It is frequently found in children and the elderly and is mostly brought on by microorganisms including fungi, bacteria, viruses, and parasites. It mainly affects persons with low immune systems.



The increased prevalence of pneumonia is a significant factor driving the expansion of the global market for therapies treating the condition. Additionally, throughout the anticipated period, an increase in the frequency of community-acquired pneumonia is anticipated to fuel market expansion. Additionally, it is anticipated that an increase in product releases following FDA clearance would assist the sector to generate the most income. Additionally, it is anticipated that a rise in clinical trials for the R&D of vaccines and medicinal compounds would support industrial expansion in the next years. The establishment of strict rules for pharmaceuticals and vaccines, however, impedes market expansion.

Impact of COVID-19 on the Global Pneumonia Therapeutics Market 
On January 30, 2021, the World Health Organization designated the COVID-19 outbreak a public health emergency of global significance. A person with COVID-19 is especially vulnerable to pneumonia, which can result in wheezing and an accumulation of mucus in the alveoli. This is anticipated to fuel the market for pneumonia treatments. Additionally, it is anticipated that growth in R&D for the treatment of pneumonia associated with COVID-19 would help the market to produce significant revenue throughout the projection period. However, the COVID-19 shortage of workers as well as resource restrictions are anticipated to have a detrimental effect on the industry's growth throughout the projection period. In addition, the industry expansion has been slowed by the installation of strict government restrictions governing lockdown. Additionally, it is urgent to develop fresh products that can aid in the fight against COVID-19. Because of this, the market for pneumonia treatments is expected to produce more money throughout the forecast period.



Scope of the Report:
 Report Metric Details
 Market size available for years 2019-2032
 Base year considered 2021
 Forecast period 2022-2032
 Segments coveredBy Access, By Component, By Type, By End User
 Geographies coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa
 Companies CoveredAtos SE, Alioth LLC, Cardcom Technology, CardLogix Corporation, CPI Card Group, Eastcompeace, Fingerprint Cards AB, Gemalto NV, Giesecke & Devrient, HID Global Corporation, IDEMIA, Infineon Technologies AG., Texas Instruments, Watchdata Technologies.
Global Pneumonia Therapeutics Market Segmentation:

By Therapeutics: Based on the Therapeutics, Global Pneumonia Therapeutics Market is segmented as; Prevention Vaccines, Treatment Drugs {Antibacterial Drugs (Macrolide, Quinolones, Aminopenicillins, Macrolides, B-lactamase inhibitors, Cephalosporins, Tetracyclines, Glycopeptide antibiotics, Carbapenems, Others), Antiviral Drugs, Antifungal Drugs}.

By Distribution Channel: Based on the Distribution Channel, Global Pneumonia Therapeutics Market is segmented as; Hospitals, Pharmaceutical Stores, Others.

By Age Group: Based on the Age Group, Global Pneumonia Therapeutics Market is segmented as; Pediatric, Adult and Geriatric.

By Infection Type: 
Based on the Infection Type, Global Pneumonia Therapeutics Market is segmented as; Hospital-acquired pneumonia, Community-acquired pneumonia, Ventilator-associated pneumonia.

By Region: Due to rising geriatric populations, an ageing population, and an increase in both adult and paediatric multidrug resistance, North America had the largest revenue share and is predicted to keep it throughout the forecast period. These factors reinforce the need for development and rising R&D activities.

1. Introduction
1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology 
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges 
4.2. COVID-19 Impacts of the Global Pneumonia Therapeutics Market

5. Market variables and outlook
5.1. SWOT analysis 
5.1.1 Strengths 
5.1.2 Weaknesses 
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis 
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape 
5.2.4 Technological landscape 
5.2.5 Environmental landscape 
5.2.6 Legal landscape 
5.3. PORTER’S five forces analysis 
5.3.1 Bargaining power of suppliers 
5.3.2 Bargaining power of Buyers 
5.3.3 Threat of Substitute 
5.3.4 Threat of new entrant 
5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Global Pneumonia Therapeutics Market, By Therapeutics, 2019-2032 (USD Million)
6.1 Prevention Vaccines
6.2 Treatment Drugs
6.2.1 Antibacterial Drugs
6.2.1.1 Macrolide
6.2.1.2 Quinolones
6.2.1.3 Aminopenicillins
6.2.1.4 Macrolides
6.2.1.5 B-lactamase inhibitors
6.2.1.6 Cephalosporins
6.2.1.7 Tetracyclines
6.2.1.8 Glycopeptide antibiotics
6.2.1.9 Carbapenems
6.2.1.10 Others
6.2.2 Antiviral Drugs
6.2.3 Antifungal Drugs

7. Global Pneumonia Therapeutics Market, By Distribution Channel, 2019-2032 (USD Million)
7.1 Hospitals
7.2 Pharmaceutical Stores
7.3 Others

8. Global Pneumonia Therapeutics Market, By Age Group, 2019-2032 (USD Million)
8.1 Pediatric
8.2 Adult
8.3 Geriatric

9. Global Pneumonia Therapeutics Market, By Infection Type, 2019-2032 (USD Million)
9.1 Hospital-acquired pneumonia (HAP)
9.2 Community-acquired pneumonia (CAP)
9.3 Ventilator-associated pneumonia (VAP)

10. Global Pneumonia Therapeutics Market, By Region, 2019-2032 (USD Million)
10.1 North America
10.1.1 United States
10.1.2 Canada
10.1.3 Mexico
10.2 Europe
10.2.1 Germany
10.2.2 United Kingdom
10.2.3 France
10.2.4 Italy
10.2.5 Spain
10.2.6 Rest of Europe
10.3 Asia-Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 Australia
10.3.5 South Korea
10.3.6 Rest of Asia-Pacific
10.4 South America
10.4.1 Brazil
10.4.2 Argentina
10.4.3 Rest of South America
10.5 Middle East & Africa
10.5.1 Kingdom of Saudi Arabia 
10.5.2 United Arab Emirates
10.5.3 Rest of Middle East & Africa

11. Company Profiles
11.1 Abbott Laboratories
11.1.1 Company details 
11.1.2 Financial outlook
11.1.3 Product summary 
11.1.4 Recent developments

11.2 Bayer AG
11.2.1 Company details 
11.2.2 Financial outlook
11.2.3 Product summary 
11.2.4 Recent developments

11.3 Eli Lilly & Company
11.3.1 Company details 
11.3.2 Financial outlook
11.3.3 Product summary 
11.3.4 Recent developments

11.4 Glaxosmithkline Plc.
11.4.1 Company details 
11.4.2 Financial outlook
11.4.3 Product summary 
11.4.4 Recent developments

11.5 Lupin Pharmaceuticals, Inc.
11.5.1 Company details 
11.5.2 Financial outlook
11.5.3 Product summary 
11.5.4 Recent developments

11.6 Merck KGAA
11.6.1 Company details 
11.6.2 Financial outlook
11.6.3 Product summary 
11.6.4 Recent developments

11.7 Novartis AG
11.7.1 Company details 
11.7.2 Financial outlook
11.7.3 Product summary 
11.7.4 Recent developments

11.8 Pfizer, Inc.
11.8.1 Company details 
11.8.2 Financial outlook
11.8.3 Product summary 
11.8.4 Recent developments

11.9 Sanofi S.A.
11.9.1 Company details 
11.9.2 Financial outlook
11.9.3 Product summary 
11.9.4 Recent developments

11.10 Teva Pharmaceuticals Industries Limited
11.10.1 Company details 
11.10.2 Financial outlook
11.10.3 Product summary 
11.10.4 Recent developments

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3


Frequently Asked Questions About This Report
The Pneumonia Therapeutics Market grew in market size from 2021. The Market is expected to reach USD 42.62 billion by 2030, at a CAGR of 8.3% during the forecast period.
The Pneumonia Therapeutics Market CAGR of 8.3% during the forecast period.
The Pneumonia Therapeutics Market is projected to reach USD 42.62 billion by 2030, growing at a CAGR of 8.3% during the forecast period.
The Pneumonia Therapeutics Market size is USD 42.62 billion from 2022 to 2030.
The Pneumonia Therapeutics Market segment is Covered By Access, By Component, By Type, By End User.
The North America region is anticipated to have the highest market share in the Pneumonia Therapeutics Market.
The key players in the market include Companies Covered Atos SE, Alioth LLC, Card com Technology, CardLogix Corporation, CPI Card Group, Eastcompeace, Fingerprint Cards AB, Gemalto NV, Giesecke & Devrient, HID Global Corporation, IDEMIA, Infineon Technologies AG., Texas Instruments, Watchdata Technologies.
It is expected that an increase in product releases following FDA approval will help the industry generate the highest revenue.
Not able to find what you are looking for? Need customization in the existing report?
Click Here
PLACE AN ORDER
  • 15% off
     
    $ 4250
  • 20% off
             
    $ 5650
  • 25% off
         
    $ 7450
Pre-Purchase Inquiry
SEND AN INQUIRY
NEED CUSTOMIZATION?
Request Customization
100% Secure Payment

SPER American Express
SPER VISA
SPER Master Card
SPER Mestro
SPER Paypal
SPER CCAvenues

Join SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB

SPER

Market Research

We are the leading, full-service global market research and consulting company.

Certificates
iso-1 iso-1
Secure Payments
SPER Payment Options
Connect with us